Compare GRFS & ORA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GRFS | ORA |
|---|---|---|
| Founded | 1940 | 1965 |
| Country | Spain | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Electric Utilities: Central |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 6.9B |
| IPO Year | 2006 | 2004 |
| Metric | GRFS | ORA |
|---|---|---|
| Price | $9.02 | $113.94 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 8 |
| Target Price | $10.15 | ★ $117.13 |
| AVG Volume (30 Days) | 551.2K | ★ 595.6K |
| Earning Date | 01-01-0001 | 11-03-2025 |
| Dividend Yield | ★ 1.58% | 0.42% |
| EPS Growth | N/A | ★ 11.26 |
| EPS | 0.64 | ★ 2.18 |
| Revenue | ★ $8,821,017,248.00 | $944,248,000.00 |
| Revenue This Year | $5.36 | $11.57 |
| Revenue Next Year | $5.15 | $17.28 |
| P/E Ratio | ★ $17.99 | $52.51 |
| Revenue Growth | ★ 7.31 | 6.07 |
| 52 Week Low | $6.19 | $61.58 |
| 52 Week High | $11.14 | $116.66 |
| Indicator | GRFS | ORA |
|---|---|---|
| Relative Strength Index (RSI) | 53.16 | 59.16 |
| Support Level | $8.69 | $110.26 |
| Resistance Level | $9.22 | $112.19 |
| Average True Range (ATR) | 0.18 | 2.72 |
| MACD | 0.03 | -0.02 |
| Stochastic Oscillator | 64.15 | 76.49 |
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.
Ormat Technologies Inc is engaged in the geothermal and recovered energy power business. It is engaged in three business segments: Electricity Segment. where the company develops, builds, owns and operates geothermal, solar PV and recovered energy-based power plants in the United States and geothermal power plants in other countries and sell the electricity generated. Product Segment includes designing, manufacturing and selling equipment for geothermal and recovered energy-based electricity generation and providing services relating to the engineering, procurement and construction of geothermal and recovered energy-based power plants. Energy Storage Segment includes owning and operating grid-connected which provide capacity, energy and ancillary services directly to the electric grid.